IP Library Granted Patent US 6,911,311
Granted Patent B2
US 6,911,311 · App. 10/040,969 · Granted Jun 28, 2005

Method of detecting protein-protein interactions

Assignee: Myriad Genetics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,911,311
App. No.
10/040,969
Granted
Jun 28, 2005
Kind
B2
Abstract

An in vitro method for detecting protein-protein interactions is provided, in which two fusion proteins are prepared and allowed to interact with each other in a substantially cell free environment. The interaction between the two fusion proteins leads to protein trans-splicing, generating an active and detectable reporter.

Claims (19)

1. A method for detecting an interaction between a first test agent and a second test agent, comprising:

providing a first fusion construct and a second fusion construct, said first fusion construct having an N-intein and said first test agent, said second fusion construct having a C-intein and said second test agent, wherein at least one of the two fusion constructs has an inactive reporter capable of being converted to an active reporter upon trans-splicing through said N-intein and said C-intein, and wherein said N-intein and said C-intein do not interact with each other;

allowing said first test agent in said first fusion construct to interact with said second test agent in said second fusion construct in vitro; and

detecting said active reporter thereby detecting a an interaction between the first and second test agent.

2. The method of claim 1 , wherein said first fusion construct comprises a first inactive reporter fused to the N-terminus of said N-intein.

3. The method of claim 2 , wherein said inactive reporter is a non-proteinaceous moiety fused to the N-terminus of said N-intein through an amino acid linker.

4. The method of claim 2 , wherein the first test agent is fused to the C-terminus of said N-intein.

5. The method of claim 2 , wherein the first test agent is covalently linked to the first inactive reporter.

6. The method of claim 2 , wherein said second fusion construct comprises a second inactive reporter fused to the C-terminus of said C-intein, and wherein an active reporter is formed upon ligation of said first and second inactive reporters.

7. The method of claim 6 , wherein said second inactive reporter is a non-proteinaceous moiety fused to the C-terminus of said C-intein through an amino acid linker selected from the group consisting of cysteine, serine, and threonine.

8. The method of claim 6 , wherein the second test agent is fused to the N-terminus of said C-intein.

9. The method of claim 6 , wherein the second test agent is covalently linked to said second inactive reporter.

10. The method of claim 1 , wherein said active reporter is detected based on molecular weight.

11. The method of claim 1 , wherein said active reporter is detected by a color assay.

12. The method of claim 11 , wherein said active reporter protein is selected from the group consisting of β-galactosidase, luciferase, green fluorescence protein, blue fluorescence protein, alkaline phosphatase, and horseradish peroxidase.

13. A method for selecting compounds capable of interfering with an interaction between a first test agent and a second test agent, comprising:

providing a first fusion construct and a second fusion construct, said first fusion construct having an N-intein and said first test agent, said second fusion construct having a C-intein and said second test agent, wherein at least one of the two fusion constructs has an inactive reporter capable of being converted to an active reporter upon trans-splicing through said N-intein and said C-intein, and wherein said N-intein and said C-intein do not interact with each other;

allowing said first test agent in said first fusion construct to interact with said second test agent in said second fusion construct in vitro and in the presence of one or more test compounds; and

detecting said active reporter thereby detecting an interaction between the first and second test agent.

Assignments (3)
CHANGE OF NAME Recorded Jul 19, 2010
From: MYRIAD PHARMACEUTICALS, INC.
To: MYREXIS, INC.
Reel/Frame 024709/0817 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2009
From: MYRIAD GENETICS, INC.
To: MYRIAD PHARMACEUTICALS, INC.
Reel/Frame 023129/0695 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2002
From: MANFREDI, JOHN
To: MYRIAD GENETICS, INC.
Reel/Frame 012789/0211 →
Continuity (2)
Provisional Application 6025975900 · Jan 4, 2001
Related Publication 20020106693A1 · Aug 8, 2002